Bailey Health Solutions describes a weight-loss program that connects an initial consultation, blood-work review, home delivery and injection instruction. For someone deciding whether to enroll, the important question is how reliably those steps connect: who evaluates the patient, what medication is ordered, which pharmacy supplies it and who responds when a problem arises. The clinic documents several parts of that journey, but not enough to reconstruct the full handoff from prescribing to ongoing care.
This review examines public documentation consulted October 19, 2026. Bailey advertises a free initial visit, a regular price of $389 per month for its compounded GLP-1 with B-12 program, and $50 off the first month. It also offers a physical office in St. Augustine, Florida, alongside telehealth access and shipping to “most states.” Those are concrete offerings, not confirmation that every reader can receive treatment. The strongest decision preparation is to separate the clinic’s described process from the operational details that still need direct confirmation.
At a glance
- Initial appointment
- A free initial visit is advertised, with consultation, discussion of compounded GLP medication with B-12, examination of current physical health and review of recent blood tests.Sources: [7]
- Published price
- The compounded GLP-1 with B-12 program is advertised at a regular $389 per month, with $50 off the first month, month-to-month pricing, no contracts, no added fees and no membership fees.Sources: [7]
- Medication handoff
- Bailey says it orders and ships compounded GLP medication with B-12 after receiving and reviewing blood work and finding the patient a suitable candidate; the consulted documentation does not identify the pharmacy or exact active ingredient.Sources: [7]
- Local and remote access
- The clinic lists 224 Southpark Circle East, St. Augustine, Florida 32086, offers office or telehealth visits, and advertises shipping to most states without naming them.
- Follow-up options
- Bailey advertises practitioner monitoring, optional weekly visits, injection demonstrations and the option for local patients to receive injections at the office.Sources: [7]
Start with access, not an assumed nationwide service
Bailey presents itself as an integrative healthcare practice combining medical and natural approaches. Its listed office is at 224 Southpark Circle East in St. Augustine, and its published telephone number is (904) 342-4941. Office hours are Monday through Friday, 9 a.m. to noon and 2 p.m. to 6 p.m. This physical location distinguishes the documented service from an exclusively online platform and provides a potential destination for local appointments.
The weight-loss page allows the first visit to take place in the office or through telehealth. It also says medication can be shipped to “most states,” but does not supply a state list. A prospective remote patient therefore needs confirmation of both clinical access and delivery availability at their address. Shipping language alone does not establish where a clinician can evaluate or prescribe, and the consulted documentation does not explain those jurisdiction-specific arrangements.
Contact can begin by telephone or through a form requesting a name, email address, phone number and service of interest. Neither route is described as an immediate prescribing channel. Readers can use the broader care-journey guide to organize questions, but Bailey itself must confirm appointment availability, the appropriate visit format and whether a particular location is served. Spanish-language care, interpretation and a patient portal are not confirmed in the consulted pages.
| Stage | What Bailey describes | What to confirm |
|---|---|---|
| First visit | Office or telehealth consultation; initial visit advertised as free | Your state’s availability and the evaluating clinician |
| Blood work | Weight-loss panel if no blood work was completed in the past year | Required tests, testing location and charges |
| Medication order | Compounded GLP medication with B-12 after review and suitability assessment | Exact formulation, prescribing professional and dispensing pharmacy |
| Delivery and instruction | Home shipping and office or telehealth injection demonstration | Arrival timing, refrigeration and when instruction occurs |
| Ongoing care | Practitioner monitoring and optional weekly visits | Scheduled reviews, response times and after-hours arrangements |
The first consultation is a screening step, not a prescription promise
The initial weight-loss visit is described as a discussion of current physical health, weight-loss goals and previous attempts to lose weight. The advertised free visit also includes questions about compounded GLP medication with B-12, an examination of current physical health and review of recent blood tests. Those are useful intake components. The pages do not explain how the examination differs between an office appointment and telehealth or identify which professional conducts each consultation.
Bailey’s potential-candidate list includes people with 25 or more pounds to lose, polycystic ovary syndrome or type 2 diabetes. It also mentions readiness to change eating habits and difficulty keeping weight off. These are the clinic’s broad marketing categories, not automatic approval criteria or a complete clinical protocol. The documentation does not provide a full account of medication-specific exclusions, contraindications or the assessment used to decide whether its particular compounded preparation is appropriate.
For preparation, NIDDK advises discussing current medicines, supplements, allergies and pregnancy plans with the treating clinician; treatment selection also involves health conditions, side effects, family history and cost. A first-consultation checklist can help organize that conversation without predetermining the result. There is also an unresolved age discrepancy: Bailey’s homepage welcomes all ages, while its terms say services, the website and communications are not intended for people under 18. Neither statement establishes a clear GLP-1 eligibility policy.
Blood-work review connects evaluation to the medication order
Bailey says it will complete a weight-loss blood panel if the patient has not had blood work within the past year. The stated purpose is to look for other issues that may hinder weight loss. The documentation does not list the tests, say where samples are collected or specify whether testing has a separate charge. Its offer to review recent blood tests also does not establish that every outside result will satisfy the program’s requirements.
The next step is explicitly conditional: after blood work is received and reviewed, Bailey says it will order and ship the compounded medication if the person is a good candidate. That sequence matters because a free visit is not a guarantee of treatment, and completion of testing is not itself approval. The pages do not give a turnaround time for results review, a deadline for a prescribing decision or an explanation of how an unsuccessful candidate is notified.
The staff page names several professionals with different roles and credentials: Jason Bailey, D.C.; Chastity Haltam, APRN; Rachel Lahav, PA; and Zehra Cumber, D.O. It identifies weight loss among Lahav’s specialties and describes nursing education for Haltam. A D.C. is a chiropractic credential, APRN denotes an advanced practice registered nurse, PA a physician assistant, and D.O. an osteopathic physician. The roster does not identify who would evaluate, prescribe or manage a particular GLP-1 patient; credentials were not independently verified for this review.
The exact preparation and pharmacy remain the largest gaps
The program is advertised as compounded GLP-1 with B-12, and its administration instructions concern injections. Although the page title mentions semaglutide, the offer’s body uses broader GLP or GLP-1 wording. That does not adequately identify the preparation a patient would receive. The consulted documentation does not establish the precise active ingredient, concentration, presentation, quantity per shipment or whether the formulation changes during care. B-12 in the program name does not fill those information gaps.
Bailey also does not identify the compounding or dispensing pharmacy, its location or its role in answering medication questions. The clinic’s statement that it will order and ship medication describes the customer-facing process, not proof that Bailey itself compounds or dispenses it. Before an order, the useful request is for the prescription details, pharmacy identity and a clear division of responsibility. Our pharmacy-handoff guide explains the distinction between a clinical decision, dispensing and delivery.
FDA says compounded preparations are not FDA approved and do not undergo its premarket review for safety, effectiveness and quality. That status alone does not establish clinical inequivalence or judge this provider’s care. FDA recommends compounded drugs for patients whose medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Bailey’s documentation does not establish that its B-12 preparation has the same outcomes as an approved product, and general drug-trial results cannot supply that missing provider-specific evidence.
Home delivery needs a plan beyond the shipping promise
Bailey says approved patients will have compounded GLP medication with B-12 shipped to their residence. It does not identify a carrier, preparation interval, dispatch window or expected arrival date. Nor does the consulted text explain tracking, missed deliveries, damaged packages or replacement responsibility. These omissions are especially relevant for remote patients, whose first practical contact with the medication may be a package rather than an office handoff. An order date should not be treated as an arrival commitment.
The page says patients return to the office or meet through telehealth for a staff demonstration of how to perform the injection. It does not specify whether that demonstration is scheduled before the shipment arrives or afterward. Local patients also have the option of visiting weekly for their injection. That is a meaningful alternative to home administration, but the office should confirm appointment arrangements, who performs the service and how it fits within the monthly program.
Refrigeration handling is another undocumented part of Bailey’s delivery process. FDA explicitly advises not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy to resolve the concern. The cold-chain guidance provides context for that advice. Before delivery, patients should know which contact handles a temperature concern and what information is needed to investigate it; the review cannot establish Bailey’s replacement or refund response.
Monitoring is promised, but its schedule is not defined
Bailey says patients will be closely monitored by a practitioner who helps determine the appropriate treatment approach. It separately advertises weekly visits as available but not required. This supports a distinction between access to visits and a mandatory review schedule: the public description does not establish weekly clinician assessment for every enrollee. It also does not explain what information is reviewed, how concerns trigger an appointment or when repeat blood work may be requested.
The clinic invites patients to call or text at any time and says it will be responsive. That is an access statement, not documented round-the-clock clinical staffing or a guaranteed response deadline. Published office hours remain weekday mornings and afternoons. Patients need a clear account of who reads messages, whether a clinician reviews medication concerns, what happens outside office hours and which channel should be used for urgent versus routine questions.
A health coach is described as discussing a customized diet plan after the patient reaches the program’s target-dose stage. That gives some sequencing detail but does not establish the number of coaching sessions or their format. NIDDK describes weight-management medication as accompanying healthy eating and physical activity, with follow-up addressing tolerance and response. Bailey’s advertised coaching and practitioner monitoring are relevant components; their practical frequency and continuity still need confirmation rather than being inferred from the monthly charge.
Monthly pricing does not settle every care expense
The published offer is specific: a regular $389 per month for the compounded GLP-1 with B-12 program, with $50 off the first month. Bailey advertises month-to-month pricing, no contracts, no added fees and no membership fees. Those claims are useful and should not be replaced with vague price uncertainty. However, the documentation does not define the exact supply quantity represented by a monthly charge or explain whether price changes with formulation or the quantity dispensed.
The free initial visit has a stated list of services, while the paid program sits alongside descriptions of medication, monitoring, optional visits and coaching. There is no detailed itemization resolving laboratory charges, injection materials, transportation costs or every possible exclusion. The “no added fees” claim should therefore be confirmed in a written, patient-specific breakdown. The pages also do not specify when the first program payment is collected relative to testing, approval, ordering or shipment.
Bailey’s homepage says many insurance plans are accepted and payment plans are available, but it does not expressly connect either statement to the GLP-1 program. NIDDK likewise cautions that medicine coverage varies by plan; acceptance for a consultation is not proof of drug coverage. Renewal dates, automatic billing, cancellation steps and refund rules are not detailed in the consulted documentation. “No contracts” and month-to-month pricing should not be read as a promise that an already collected payment will be refunded.
Communication terms deserve attention before enrollment
The terms identify the business as Bailey Health Solutions and carry an effective date of October 1, 2023. The contact form’s marketing-text consent instead names Bailey Spine & Wellness LLC. The public documentation does not explain the relationship between those names. That discrepancy is not proof of wrongdoing, but it is a practical reason to ask which entity provides clinical services, processes payments, maintains records and sends messages before submitting consent or enrolling.
The terms say SMS consent is not a condition of receiving services and describe replying STOP to end text messages. That action concerns communications; it is not a documented method for canceling treatment or recurring charges. The privacy notice says mobile numbers and SMS opt-in data are not sold, rented or shared for third-party marketing or promotional purposes. It also discloses cookies and tracking technologies for the website and relevant marketing communications.
For care continuity, the privacy notice recognizes access to an electronic health record and requests to send it directly to a third party. It also offers to accommodate reasonable requests for privacy-preserving communications. These are useful documented paths if care changes hands. The terms separately state that website information does not establish a provider-patient relationship. Consequently, reading the offer, filling out a contact form and receiving actual clinical responsibility should not be treated as interchangeable stages.
Questions & answers
Can I use Bailey Health Solutions without visiting St. Augustine?
The clinic describes telehealth for the initial consultation and injection demonstration, plus home delivery. It says medication can ship to most states but does not name them. Ask whether your location is supported for both clinical care and dispensing, and whether any part of your assessment requires an office visit. The documentation does not establish nationwide availability or explain where remote patients complete required blood work.
Does the free consultation include free medication or laboratory testing?
The advertised free initial visit includes consultation, questions about compounded GLP medication with B-12, examination of current physical health and review of recent blood tests. It does not expressly promise free medication or newly ordered laboratory testing. The separate program has a regular $389 monthly price with $50 off the first month. Ask for laboratory and other service charges to be reconciled with Bailey’s “no added fees” advertising before proceeding.
Will Bailey prescribe a specific brand-name GLP-1 medicine?
The documented offer is for compounded GLP-1 medication with B-12, not a confirmed brand-name prescription pathway. Although the page title references semaglutide, the body does not adequately identify the exact preparation to be dispensed. Request the active ingredient, formulation, concentration, presentation and pharmacy details. FDA approval applies to specific products; a compounded preparation is not FDA approved, and the clinic’s program should not be described as FDA approved.
Are weekly office visits required?
No. Bailey explicitly describes weekly visits as optional, and local patients may come to the office weekly for an injection. That does not mean follow-up itself is unnecessary or that every remote patient receives weekly clinical contact. Ask what monitoring is scheduled for you, how medication concerns are reviewed and whether optional visits or administration services have any limitations under the advertised monthly price.
What should I clarify before the first shipment?
Obtain the dispensing pharmacy’s name, expected dispatch and arrival timing, refrigeration instructions and a contact for damaged or temperature-compromised deliveries. Bailey’s public description does not settle those details. Also arrange the promised injection demonstration and clarify instructions with the prescriber or pharmacist rather than calculating a dose from online material. FDA advises not using an injectable GLP-1 drug that arrives warm or insufficiently refrigerated and contacting the provider or pharmacy.
Does replying STOP cancel the monthly program?
The documented STOP instruction ends SMS messages; it does not establish cancellation of clinical services or billing. Bailey advertises month-to-month pricing without contracts, but the consulted pages do not spell out cancellation deadlines, renewal mechanics or refunds. Request those terms directly, including which office contact accepts cancellation and how it is confirmed. Ending marketing consent, ending treatment and disputing a charge are separate matters that should not be assumed to share one process.
Our assessment
Bailey Health Solutions documents a recognizable hybrid care pathway: a free initial consultation, conditional blood-work review, compounded GLP-1 medication with B-12 shipped home, injection instruction and practitioner monitoring. Its physical office, optional weekly visits and published monthly price give prospective patients concrete features to assess. The principal weakness is the incomplete handoff documentation: the exact preparation, dispensing pharmacy, available states, delivery safeguards, monitoring schedule and billing exit process remain unresolved. Those gaps do not prove that the services are absent, but they prevent a complete assessment of how care would work for a particular patient. Before paying, obtain a written account connecting the responsible clinician, prescription, pharmacy, shipment, follow-up and cancellation terms. The free consultation is a useful opportunity to request those details, not a reason to assume they are already settled.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Wilding et al. (2021): STEP 1 semaglutide trial ↗
- Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
- Bailey Health Solutions — official website ↗
- Bailey Health Solutions — contact ↗
- Bailey Health Solutions — glp1weightloss ↗
- Bailey Health Solutions — terms and conditions ↗
- Bailey Health Solutions — meet the team ↗
- Bailey Health Solutions — notice of privacy practices ↗